Literature DB >> 23933889

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23933889     DOI： 10.1007/s11912-013-0338-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  19 in total

Review 1.  Second-line treatment of ovarian cancer.

Authors:  M Markman; M A Bookman
Journal:  Oncologist       Date:  2000

Review 2.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

Authors:  Maurie Markman; Joan L Walker
Journal:  J Clin Oncol       Date:  2006-02-06       Impact factor: 44.544

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

6.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

8.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Authors:  Bradley J Monk; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Jan B Vermorken; Franco M Muggia; Eric Pujade-Lauraine; Alla S Lisyanskaya; Anatoly N Makhson; Janusz Rolski; Vera A Gorbounova; Prafull Ghatage; Mariusz Bidzinski; Keng Shen; Hextan Yuen-Sheung Ngan; Ignace B Vergote; Joo-Hyun Nam; Youn Choi Park; Claudia A Lebedinsky; Andrés M Poveda
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

9.  Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Authors:  Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Journal:  Gynecol Oncol       Date:  2009-05-17       Impact factor: 5.482

10.  Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

Authors:  Lisa M Landrum; James Java; Cara A Mathews; Grainger S Lanneau; Larry J Copeland; Deborah K Armstrong; Joan L Walker
Journal:  Gynecol Oncol       Date:  2013-04-08       Impact factor: 5.482
View more
  1 in total

1.  Caregiver Burden in End-Stage Ovarian Cancer.

Authors:  Joan Hartnett; Bridgette Thom; Nancy Kline
Journal:  Clin J Oncol Nurs       Date:  2016-04       Impact factor: 1.027
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.